12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Diagnosis of type 2 diabetes

• Hb1AC >7%-11% inclusive

• Male and females 18-70; females must be post-menopausal

• On a stable dose of metformin hydrochloride

Exclusion Criteria:

• Medical history of stroke, unstable angina, heart attack within one year of enrollment, and alcohol dependency or recent drug abuse.

• Women of childbearing potential, pregnant or nursing

• Evidence of diabetic complications with significant end-organ damage